PV Bulletin

FDA Study Data Technical Conformance Guide Update

FDA updated the Study Data Technical Conformance Guide, affecting submission requirements for clinical trial and post-marketing study data.

Primary source: Food and Drug Administration (FDA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

Sponsors and Marketing Authorization Holders (MAHs) must ensure that clinical trial and post-marketing study data submissions comply with the updated technical specifications outlined in the FDA's latest guidance.

Why it matters

Failure to comply with updated specifications could result in submission rejection or delays in the safety review process, impacting regulatory timelines and organizational responsibilities.

Action needed

Review and update data submission practices to align with the new technical specifications; ensure compliance with FDA-supported data standards.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Technical Guidance
Policy status
revised
Publication date
12 June 2026
Policy change
FDA published an updated version of the Study Data Technical Conformance Guide, providing technical specifications for the submission of study data. This document represents the Agency's current thinking on the technical conformance of study data submissions in electronic format.

Key changes

Updates to technical specifications for study data submissions; refined guidance on conformance with FDA-supported data standards (e.g., CDISC SDTM/ADaM).

Affected workflows

ICSRCountry Compliance

Responsible groups

Clinical Data ManagementPV OperationsRegulatory Affairs

PV impact

Sponsors and MAHs submitting clinical trial or post-marketing study data (e.g., for DSURs or PASS) must ensure their data sets comply with the updated technical specifications. Conformance failures can lead to submission rejection or delays in safety reviews.

View regulator source

Source document details

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 12, 2026

Full briefing

Practical implication

Review and update data submission practices to align with the new technical specifications; ensure compliance with FDA-supported data standards.

FDA published an updated version of the Study Data Technical Conformance Guide, which provides technical specifications for the electronic submission of study data. This change refines requirements regarding compliance with FDA-supported data standards like CDISC SDTM/ADaM. Non-compliance may lead to rejection of submissions or delays in safety reviews.

What changed: Sponsors and Marketing Authorization Holders (MAHs) must ensure that clinical trial and post-marketing study data submissions comply with the updated technical specifications outlined in the FDA's latest guidance.

Why it matters: Failure to comply with updated specifications could result in submission rejection or delays in the safety review process, impacting regulatory timelines and organizational responsibilities.

Practical implication: Review and update data submission practices to align with the new technical specifications; ensure compliance with FDA-supported data standards.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Country Guides#Technical Guidance#Revised#Food and Drug Administration (FDA)#reporting_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward